ReviewCell adhesion & migration2025
The research trends and hotspots of claudins in the field of cancer.
Review in Cell adhesion & migration, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The claudin family characteristics in pan-cancer and the role of claudin12 in the malignant progression of lung adenocarcinoma.Scientific reports · 2025Article
- Listening to the Past, Shaping the Future: A Data-mining Based and Visual Analysis of Five Decades of Gastric Carcinogenesis Research.Biological procedures online · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Claudins (CLDNs), as the key components of tight junctions, have been implicated as key factors in carcinogenesis and metastasis. A total of 1720 publications on CLDNs in the field of cancer were published from January 2005 to December 2022. The United States dominates the research on CLDNs in cancer, followed by China. China Medical University is the most productive, and Johns Hopkins University has the most citations. Morin PJ is credited with initiating research on CLDNs in cancer. CLDN18, the intestinal barrier, and the intestinal microbiota are the focus and hotspots in this field. The mechanism of CLDN-mediated metastasis still needs further investigation, and the development of CLDN-targeted therapies also needs to be explored in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.